LANGHORNE, PA — NEXGEL, Inc. (Nasdaq: NXGL) appointed orthopedic and biologics sales executive Dave Hazard as vice president of sales for its BIONX Surgical division as the company seeks to scale commercialization efforts following a recent acquisition.
The appointment comes as NEXGEL expands BIONX Surgical, a business focused on tissue and hydrogel products used across orthopedic, sports medicine, wound care, and surgical applications.
Hazard previously worked at Nuo Therapeutics, Inc., where he helped commercialize platelet-rich plasma wound care products and built a sales organization of more than 400 representatives, according to the company.
Before joining Nuo Therapeutics, Hazard spent more than five years at Arthrex, Inc. overseeing orthobiologics sales operations that generated more than $50 million in annual revenue across orthopedic and sports medicine markets.
NEXGEL Chief Executive Officer Adam Levy said the company is focused on building sales infrastructure and expanding strategic partnerships as BIONX Surgical grows.
“He has a proven ability to build scalable sales infrastructure and establish the kind of enterprise partnerships that drive repeatable revenue,” Levy stated.
Hazard said the company’s existing partnerships and product portfolio position BIONX Surgical for expansion across multiple medical specialties.
“We are well positioned to serve patients across sports medicine, orthopedics, plastics, wound care, and others with our robust tissue and hydrogel products,” Hazard stated.
NEXGEL manufactures hydrogel-based healthcare and consumer products, including wound care and over-the-counter applications.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.